Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Table 1

The blood glycemic fluctuation parameters within groups. Data were presented as means ± SD. a:  , dapagliflozin group versus placebo group.

Items	Dapa group			Placebo group			Dapa versus placebo
	Before	After	value	Before	After	value	value (after)
MBG	10.12 ± 1.77	7.50 ± 1.49	0.031	11.01 ± 2.20	9.46 ± 1.16	0.068	0.010
SDMBG	2.43 ± 1.09	1.51 ± 0.42	0.042	2.04 ± 0.62	1.75 ± 0.62	0.452	0.338
MAGE	5.85 ± 3.02	3.48 ± 0.98	0.038	5.76 ± 1.38	5.37 ± 2.16	0.357	0.026
AUC > 10	0.69 ± 1.15	0.14 ± 0.28	0.140	1.73 ± 1.71	0.44 ± 0.47	0.120	0.119
AUC < 3.9	0.00 ± 0.00	0.02 ± 0.06	0.343	0.00 ± 0.00	0.00 ± 0.00	—	0.420
AUC-FPG	1.68 ± 0.50	1.01 ± 0.65	0.044	1.62 ± 0.74	1.12 ± 0.80	0.152	0.524

Dapa group: dapagliflozin group; before: before therapy; after: after therapy; MBG: mean blood glucose (mmol/L); SDMBG: standard deviation of mean blood glucose (mmol/L); MAGE: mean amplitude of glycemic excursions (mmol/L); AUC > 10: the incremental area under curve of plasma glucose > 10.0 mmol/L (mmol/L per day); AUC < 3.9: the incremental area under curve of plasma glucose < 3.9 mmol/L (mmol/L per day); AUC-FPG: the incremental area under curve above fasting plasma glucose (mmol/L per day).